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Hepatocellular carcinomaTo elucidate the molecular feature of human hepatocellular carcinoma (HCC), we performed 5′-end serial
analysis of gene expression (5′SAGE), which allows genome-wide identiﬁcation of transcription start sites in
addition to quantiﬁcation of mRNA transcripts. Three 5′SAGE libraries were generated from normal human
liver (NL), non-B, non-C HCC tumor (T), and background non-tumor tissues (NT). We obtained 226,834 tags
from these libraries and mapped them to the genomic sequences of a total of 8,410 genes using RefSeq
database. We identiﬁed several novel transcripts speciﬁcally expressed in HCC including those mapped to
the intronic regions. Among them, we conﬁrmed the transcripts initiated from the introns of a gene encoding
acyl-coenzyme A oxidase 2 (ACOX2). The expression of these transcript variants were up-regulated in HCC
and showed a different pattern compared with that of ordinary ACOX2 mRNA. The present results indicate
that the transcription initiation of a subset of genes may be distinctively altered in HCC, which may suggest
the utility of intronic RNAs as surrogate tumor markers.xpression; HCC, hepatocellular
).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common cancer
worldwide and the thirdmost common cause of cancermortality. HCC
usually develops in patients with virus-induced (e.g., hepatitis B virus
(HBV) and hepatitis C virus (HCV)) chronic inﬂammatory liver disease
[1]; however, non-B, non-C HCC has been reported in patients
negative for both HBV and HCV [2]. HCC development is a multistep
process involving changes in host gene expression, some of which are
correlated with the appearance and progression of a tumor. Multiple
studies linking hepatitis viruses and chemical carcinogens with
hepatocarcinogesis have provided insights into tumorigenesis [1,3].
Nevertheless, the genetic events that lead to HCC development
remain unknown, and the molecular pathogenesis of HCC in most
patients is still unclear. Therefore, elucidation of the genetic changes
speciﬁc to the pathogenesis of non-B, non-C HCC may be useful to
reveal the molecular features of HCCs irrelevant to viral infection.
Gene expression proﬁling, either by cDNA microarray [4] or serial
analysis of gene expression (SAGE) [5], is a powerful molecular
technique that allows analysis of the expression of thousands ofgenes. In particular, SAGE enables the rapid, quantitative, and
simultaneous monitoring of the expression of tens of thousands of
genes in various tissues [6,7]. Although numerous studies using cDNA
microarrays and SAGE have been performed to clarify the genomic
and molecular alterations associated with HCC [6,8–10], most
expression data have been derived from the 3′-end region of mRNA.
Recent advances in molecular biology have enabled genome-wide
analysis of the 5′-end region of mRNA that revealed the variation in
transcriptional start sites [11,12] and the presence of a large number
of non-coding RNAs [13]. These approaches might be useful for
identifying the unique and undeﬁned genes associated with HCC not
identiﬁed by the analysis of the 3′-end region of mRNA. SAGE based
on the 5′-end (5′SAGE), a recently developed technique, allows for a
comprehensive analysis of the transcriptional start site and quanti-
tative gene expression [14]. This article is to elucidate the molecular
carcinogenesis of non-B, non-C HCCs, while those heterogeneous
entities are supposed not to share the same etiology, by using 5′SAGE.
Results
Annotation of the 5′SAGE tags to the human genome
We characterized a total of 226,834 tags from three unique 5′SAGE
libraries (75,268 tags from the normal liver (NL) library, 75,573 tags
from the non-tumor tissue (NT) library, and 75,993 tags from the
tumor (T) library) and compared them against the human genome
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representing 104,820 different tags in the three libraries (Table 1).
About 60–65% of these tags mapped to a single locus in the genome in
each library. Then, we mapped these single-matched tags to the well-
annotated genes using RefSeq database (www.ncbi.nlm.nih.gov/
RefSeq/, reference sequence database developed by NCBI). A total of
45,601 tags from the NL library, 39,858 from the NT library, and
41,265 from the T library were successfully mapped to 8410 unique
genes (4397 genes detected in the NL library, 5194 genes in the NT
library, and 6304 genes in the T library).
Gene expression proﬁling of non-B, non-C HCC
Abundantly expressed transcripts in the NL library and their
corresponding expression in the NT and T libraries are shown in
Table 2. Themost abundant transcript in all three libraries was encoded
by the albumin (ALB) gene. Transcripts encoding apolipoproteins were
also abundantly expressed in each library, suggesting the preservation
of hepatocytic gene expression patterns in HCC. Of note, the expression
of haptoglobin (HP) (NL: 631, NT: 329, T: 57) and metallothionein 1G
(MTIG) (NL: 392, NT: 169, T: 2) was decreased in the NT library and
more in T library comparedwithNL library. Furthermore, the expression
ofmetallothionein 2A (MT2A) (NL: 1027, NT: 872, T: 19),metallothionein
1X (MT1X) (NL: 547, NT: 644, T: 11), andmetallothionein 1E (MT1E) (NL:
275, NT: 340, T: 2) was decreased almost ﬁfty-fold or more in the T
library compared with the NL and NT libraries. In contrast, the
expression of ribosomal protein S29 (RPS29) (NL: 372, NT: 1011, T:
1768) was increased in the NT library and more in T library compared
withNL library. Thus, transcripts associatedwith a certain liver function
including xenobiotic metabolism might be suppressed whereas those
associated with protein synthesis might be expressed in non-B, non-C
HCC, similar to that observed in HCV-HCC [15].
We then investigated the characteristics of gene expression
patterns in non-B, non C HCC. Two hundred ﬁfty-four and 172
genes were up- or down-regulated in the T library more than ﬁve-fold
compared with the NL library (data not shown). The top 10 genes are
listed in Table 3a, and we identiﬁed several novel genes not yet
reported to be differentially expressed in non-B, non-C HCC.
Representative novel gene expression changes identiﬁed by 5′SAGE
were validated by semi-quantitative reverse transcriptase-polymer-
ase chain reaction (RT-PCR) analysis (Supplemental Fig. 1). RT-PCR
results showed that the expression of galectin 4 (LGALS4), X antigen
family, member 1A (XAGE 1A), retinol dehydrogenase 11 (RDH11), hy-
droxysteroid (17-beta) dehydrogenase 14 (HSD17B14) transmembrane
14A (TMEM14A), stimulated by retinoic acid 13 homolog (STRA13), and
dual speciﬁcity phosphatase 23 (DUSP23) was increased, whereas the
expression of C-type lectin superfamily 4 member G (CLEC4G) was
decreased in HCC tissues compared with the non-tumor tissues.
To further characterize the gene expression patterns of non-B,
non-C HCC comprehensively, we compared the Gene Ontology
process of three types of HCCs (i.e., non-B, non-C HCC; HBV-HCC;Table 1
Experimental matching of 5′SAGE tags to genome.
Normal liver Non-t
All tags 75,268 75,57
Tags mapped to genome (%)
1 locus/genome 51,076 (71.2) 47,20
Multiple loci/genome 20,608 (28.8) 22,14
Total tags 71,684 (100) 69,34
Unique tags mapped to genome (%)
1 locus/genome 20,736 (65.5) 20,48
Multiple loci/genome 10,914 (34.5) 13,54
Total tags 31,650 (100) 34,03
Total tags to RefSeq 45,601 39,85
Unique gene 4397 5194
5′SAGE indicates 5′-end serial analysis of gene expression.HCV-HCC) based on our previously described data [16]. The pathway
analysis using MetaCore™ software showed that the immune related
and cell adhesion related pathways were up-regulated in HCV-HCC
with statistically signiﬁcance, and the insulin signaling and angio-
genesis related pathways were up-regulated in HBV-HCC with
statistically signiﬁcance, conﬁrming our previous results [16]. Inter-
estingly, genes associated with progesterone signaling were up-
regulated in non-B, non-C HCC, while genes associated with
proteolysis in the cell cycle, apoptosis and the ESR1-nuclear pathway
were up-regulated in all types of HCC (Supplemental Fig. 2).
Dynamic alteration of transcription initiation in HCC
Although various transcriptome analyses have discovered consider-
able gene expression changes in cancer, it is still unclear if transcription
is differentially initiated and/or terminated in HCC compared with the
non-cancerous liver. We therefore explored the characteristics of
transcription initiation and/or termination in HCC using 5′SAGE and
3′SAGE data. Markedly, we observed relevant differences between 5′
SAGE and 3′SAGE data derived from the same HCC sample (Tables 3a
and b). For example, a gene encoding coagulation factor XIII, B
polypeptide (F13B) was 13-fold up-regulated at transcription start
sites (5′SAGE) but two-fold down-regulated at transcription termina-
tion sites (3′SAGE). On the other hand, a gene encoding adenylate
cyclase 1 (ADCY1) was 50-fold down-regulated at transcriptional
termination sites (3′SAGE) but showed no difference at transcriptional
start sites (5′SAGE). These data suggest the dramatic alteration of all
process of transcription in HCC, and the transcripts initiated at certain
sites might be speciﬁcally associated with and involved in HCC
pathogenesis, which could be a novel marker for HCC diagnosis.
Identiﬁcation of novel intronic transcripts in HCC
Recent lines of evidence suggest that the majority of sequences of
eukaryotic genomes may be transcribed, not only from known
transcription start sites but also from intergenic regions and introns
[17,18]. Introns are recognized as a signiﬁcant source of functional
non-coding RNAs (ncRNAs) including microRNAs (miRNAs) [18].
Moreover, a recent report implied the role of some large intronic RNAs
in the pathogenesis of several types of malignancies [19]. Thus,
analysis of transcripts originating from introns might be valuable for
elucidating the genetic traits of HCC. We therefore focused on the
transcriptional start sites potentially initiated from the intron and
deregulated in HCC using 5′SAGE data. We identiﬁed that 97% of 5′
SAGE tags annotated by the RefSeq database matched the sequences
in the exons, while 3% matched those in the introns (1257 in the N
library, 1225 in the NT library, and 1261 in the T library) (Table 4a). To
identify the possible promoter regions located in the intron, we
clustered the different SAGE tags to a certain genomic region if these
tags positioned within 500 bp intervals (Supplemental Fig. 3), as
described previously [12].umor Tumor Total
3 75,993 226,834
0 (68.0) 48,503 (68.5) 146,779 (69.3)
2 (32.0) 22,289 (31.5) 65,039 (30.7)
2 (100) 70,792 (100) 211,818 (100)
7 (60.2) 23,753 (60.7) 64,976 (62.0)
8 (39.8) 15,382 (39.3) 39,844 (38.0)
5 (100) 39,135 (100) 104,820 (100)
8 41,265 126,724
6304 8410
Table 2
The highly expressed genes in the NL library and corresponding expression in the NT
and T libraries (top 50 from NL library).
Tag count Ratio Gene
NL NT T NT/
NL
T/NL
3731 1716 2328 0.460 0.624 Albumin (ALB)
2484 2146 2042 0.864 0.822 Apolipoprotein C-I (APOC1)
1955 1603 1079 0.820 0.552 Apolipoprotein A-II (APOA2)
1653 1050 828 0.635 0.501 Apolipoprotein A-I (APOA1)
1252 1908 1203 1.524 0.961 Transthyretin (prealbumin,
amyloidosis type I) (TTR)
1233 724 220 0.587 0.178 Serpin peptidase inhibitor, clade A,
member 1 (SERPINA1)
1027 872 19 0.849 0.019 Metallothionein 2A (MT2A)
755 1144 762 1.515 1.009 Ferritin, light polypeptide (FTL)
713 632 680 0.886 0.954 Alpha-1-microglobulin/bikunin precursor
(AMBP)
635 524 1336 0.825 2.104 Apolipoprotein E (APOE)
631 329 57 0.521 0.090 Haptoglobin (HP)
600 228 212 0.380 0.353 Fibrinogen gamma chain (FGG)
549 395 302 0.719 0.550 Apolipoprotein C-III (APOC3)
547 644 11 1.177 0.020 Metallothionein 1X (MT1X)
479 257 290 0.537 0.605 Tumor protein, translationally-controlled 1
(TPT1)
463 217 53 0.469 0.114 Serpin peptidase inhibitor, clade A,
member 3 (SERPINA3)
393 204 206 0.519 0.524 Ribosomal protein L26 (RPL26)
392 169 2 0.431 0.005 Metallothionein 1G (MT1G)
372 1011 1768 2.718 4.753 Ribosomal protein S29 (RPS29)
306 163 223 0.533 0.729 Ribosomal protein S27 (RPS27)
279 135 159 0.484 0.570 Ribosomal protein S16 (RPS16)
275 340 2 1.236 0.007 Metallothionein 1E (MT1E)
269 170 246 0.632 0.914 Ribosomal protein S23 (RPS23)
260 142 92 0.546 0.354 Fibrinogen beta chain (FGB)
260 200 195 0.769 0.750 Aldolase B, fructose-bisphosphate (ALDOB)
255 228 286 0.894 1.122 Ribosomal protein S12 (RPS12)
248 162 198 0.653 0.798 Ribosomal protein S14 (RPS14)
246 175 70 0.711 0.285 Interferon induced transmembrane
protein 3 (IFITM3)
239 198 273 0.828 1.142 Ribosomal protein L31(RPL31)
229 264 0 1.153 0.004 Hepcidin antimicrobial peptide (HAMP)
228 149 156 0.654 0.684 Ribosomal protein S20 (RPS20)
222 191 117 0.860 0.527 Ubiquitin B (UBB)
216 218 352 1.009 1.630 Ribosomal protein L41 (RPL41)
210 150 155 0.714 0.738 Ribosomal protein, large, P1(RPLP1)
201 110 90 0.547 0.448 Ribosomal protein, large, P2 (RPLP2)
198 102 64 0.515 0.323 Fibrinogen alpha chain (FGA)
196 143 408 0.730 2.082 Ribosomal protein L37 (RPL37)
192 123 56 0.641 0.292 Ribosomal protein L37a (RPL37A)
191 208 346 1.089 1.812 Ribosomal protein L30 (RPL30)
174 109 76 0.626 0.437 Ribosomal protein L35 (RPL35)
169 208 3 1.231 0.018 Cytochrome P450, family 2, subfamily E,
polypeptide 1 (CYP2E1)
167 105 300 0.629 1.796 Apolipoprotein H (beta-2-glycoprotein I)
(APOH)
162 106 33 0.654 0.204 Serum amyloid A4, constitutive (SAA4)
159 85 157 0.535 0.987 Ribosomal protein L34 (RPL34)
159 113 229 0.711 1.440 Transferrin (TF)
155 84 135 0.542 0.871 Ribosomal protein S11 (RPS11)
152 125 101 0.822 0.664 Ribosomal protein S13 (RPS13)
147 84 1 0.571 0.007 Nicotinamide N-methyltransferase (NNMT)
147 180 35 1.224 0.238 Hemopexin (HPX)
146 89 121 0.610 0.829 Alpha-2-HS-glycoprotein (AHSG)
To avoid division by 0, a tag value of 1 for any tag that was not detectable was used.
NL, normal liver; NT, non-tumor; T, tumor.
Table 3a
Differently expressed genes in HCC (top 10 from 5′SAGE).
5′SAGE 3′SAGE 5′/3′ Gene
T/NL T/NL Ratio
Up-regulated gene
19 6 3.17 P antigen family, member 2 (prostate associated)
(PAGE2)
18 10 1.8 Lectin, galactoside-binding, soluble, 4 (LGALS4)
16 3 5.33 Choline phosphotransferase 1 (CHPT1)
14 2 7 X antien family, member 1A (XAGE1A)
14 2 7 Dehydrogenase/reductase (SDR family) member 4
(DHRS4)
14 2 7 Sterol-C5-desaturase-like (SC5DL)
13 0.5 26 Coagulation factor XIII, B polypeptide (F13B)
13 2.33 5.58 Retinol dehydrogenase 11 (all-trans and 9-cis) (RDH11)
13 0.5 26 Transmembrane protein 14A (TMEM14A)
12 1.33 9.02 Dual speciﬁcity phosphatase 23 (DUSP23)
Down-regulated gene
0.00436 0.0137 0.318 Hepcidin antimicrobial peptide (HAMP)
0.0051 ND Metallothionein 1G (MT1G)
0.0068 0.04 0.17 Nicotinamide N-methyltransferase (NNMT)
0.00727 ND Metallothionein 1E (functional) (MT1E)
0.0098 0.0526 0.186 C-reactive protein, pentraxin-related (CRP)
0.0145 ND Metallothionein 1 M (MT1M)
0.0152 ND Phospholipase A2, group IIA (platelets, synovial ﬂuid)
(PLA2G2A)
0.0178 0.111 0.16 Cytochrome P450, family 2, subfamily E, polypeptide 1
(CYP2E1)
0.0185 0.192 0.096 Metallothionein 2A (MT2A)
0.0201 ND Metallothionein 1X (MT1X)
3′SAGE, 3′-end serial analysis of gene expression; 5′SAGE, 5′-end serial analysis of gene
expression; HCC, hepatocellular carcinoma; NL, normal liver; T, tumor.
Table 3b
Differently expressed genes in HCC (top 10 from 3′SAGE).
5′SAGE 3′SAGE 5′/3′ Gene
T/NL T/NL Ratio
Up-regulated gene
ND 15 Leukocyte immunoglobulin-like receptor,
subfamily B, member 1 (LILRB1)
ND 12 Fibroblast growth factor 5 (FGF5)
1 11 0.909 Adenosine deaminase, tRNA-speciﬁc 1 (ADAT1)
5 11 0.454 px19-like protein (PRELID1)
4.4 11 0.4 Anaphase promoting complex subunit
11 (ANAPC11)
ND 10.3 Chromosome 21 open reading frame 77 (C21orf77)
ND 10 von Willebrand factor (VWF)
2.333 10 0.233 ATX1 antioxidant protein 1 homolog (yeast)
(ATOX1)
18 10 1.8 Lectin, galactoside-binding, soluble, 4 (LGALS4)
ND 9.5 Solute carrier family 26 (sulfate transporter),
member 2 (SLC26A2)
Down-regulated gene
0.5 0.012 41.7 ELL associated factor 1 (EAF1)
0.5 0.0137 36.5 TGF beta-inducible nuclear protein 1 (NSA2)
0.000436 0.0137 0.032 Hepcidin antimicrobial peptide (HAMP)
1 0.0179 55.9 Basic, immunoglobulin-like variable motif containing
(BIVM)
ND 0.0182 DNA fragmentation factor, 45 kDa, alpha polypeptide
(DFFA)
1 0.0185 54.1 GRIP1 associated protein 1 (GRIPAP1)
ND 0.0189 Nuclear factor of activated T-cells 5,
tonicity-responsive (NFAT5)
1 0.0204 49 Adenylate cyclase 1 (ADCY1)
0.333 0.0312 10.7 Dihydroorotate dehydrogenase (DHODH)
0.738 0.0312 23.7 Ribosomal protein, large, P1 (RPLP1)
3′SAGE, 3′-end serial analysis of gene expression; 5′SAGE, 5′-end serial analysis of gene
expression; HCC, hepatocellular carcinoma; NL, normal liver; T, tumor.
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genes in the NL, 168 genes in the NT, and 157 genes in the T library,
suggesting that these regions might be potential intronic promoter
regions (Table 4a). The biological process of these intron-origin
transcripts using Human Protein Reference Database (http://www.
hprd.org/) showed that these were related to basic cellular functions
such as signal transduction, transport, and regulation of the
nucleobase and nucleotide, suggesting that these intronic transcriptsmay play a fundamental role in the liver (data not shown). Among
these genes, 12 were differentially expressed between the NL and T
libraries more than four-fold (Table 4b). Interestingly, intronic
transcripts (determined by 5′SAGE) of genes encoding SAMD3,
Table 4a
Number of 5′SAGE tags mapped to intronic region.
NL NT T
Tag mapped to intron 1287 1253 1292
Total promoter region 952 981 1020
(tag number=1) 788 813 863
(tag number ≧2) 164 168 157
220 Y. Hodo et al. / Genomics 95 (2010) 217–223ACOX2, HGD, CYP3A5, KNG1 and AGXT were increased, while their 3′
transcripts (determined by 3′SAGE) were decreased in HCC. In
contrast, both 5′ intronic transcripts and 3′ transcripts encoding
HFM1, SERPINA1, SUPT3H, A2M and TMEM176B were similarly
decreased in HCC. Taken together, these data imply that the
canonical- and intronic-promoter activities of a subset of genes
including SAMD3, ACOX2, HGD, CYP3A5, KNG1 and AGXT might be
differently regulated in HCC.
ACOX2 as a novel intronic gene deregulated in HCC
A subset of genes listed above may be transcribed from intronic
regions speciﬁcally in HCC. Among these genes, we focused on the
regulation of ACOX2, which is reported to be potentially involved in
peroxisomal beta-oxidation and hepatocarcinogenesis [20]. The
intron-origin expression of ACOX2 increased six-fold in HCC
compared with the NT by 5′SAGE, while the expression based on
the 3′end was almost similar between HCC and NT lesions (Table 4b).
Close examination of 5′SAGE data identiﬁed two potential intron-
origin transcripts of ACOX2 (Supplemental Fig. 4). The ﬁrst (intronic-
ACOX2-1) was initiated upstream of the tenth exon, whereas the
second (intronic-ACOX2-2) was initiated upstream of the twelfth
exon of ACOX2 (Supplemental Fig. 4). The sequence of the intronic
part was unique, and the remaining part of the sequence was shared
with the canonical transcripts of ACOX2.
The expression of canonical ACOX2 and the two types of intron-
origin transcripts was investigated in NL, NT, and T tissues by RT-PCR
(Fig. 1A). Although canonical ACOX2 expression was decreased in T
than in NL, the intron-origin transcript, particularly intronic-ACOX2-1,
was increased in T. Intronic-ACOX2-2 transcripts also showed a
modest increase. We further evaluated the alteration of theseTable 4b
Differentially expressed intronic promoter regions in HCC.
5′SAGE 3′SAGE 5′/3′ Gene
T/NL T/NL Ratio
Up-regulated
9 1 9.00 Sterile alpha motif domain containing 3 (SAMD3)
6 0.89 6.74 Acyl-Coenzyme A oxidase 2, branched chain (ACOX2)
6 0.62 9.68 Homogentisate 1,2-dioxygenase (homogentisate
oxidase) (HGD)
6 0.009 666.67 Cytochrome P450, family 3, subfamily A, polypeptide
5 (CYP3A5)
5 0.64 7.81 Kininogen 1 (KNG1)
4 0.36 11.11 Alanine-glyoxylate aminotransferase (AGXT)
4 1 4.00 Crystallin, alpha A (CRYAA)
Down-regulated
0.13 1 0.13 HFM1, ATP-dependent DNA helicase homolog
(S. cerevisiae) (HFM1)
0.25 0.51 0.49 Serpin peptidase inhibitor, clade A member 1
(SERPINA1)
0.25 1 0.25 Suppressor of Ty 3 Homolog (S. cerevisiae) (SUPT3H)
0.25 0.2 1.25 Alpha-2-macroglobulin (A2M)
0.25 0.083 3.13 Transmembrane protein 176B (TMEM176B)
3′SAGE, 3′-end serial analysis of gene expression; 5′SAGE, 5′-end serial analysis of gene
expression; HCC, hepatocellular carcinoma; NL, normal liver; NT, non-tumor; T, tumor.transcripts in 19 HBV-HCCs, 20 HCV-HCCs, and 4 non-B, non-C
HCCs, and their background liver tissues by canonical ACOX2 and
intronic-ACOX2 speciﬁc real-time detection (RTD)-PCR. Although the
expression of canonical ACOX2 was decreased, the expression of
intronic-ACOX2was signiﬁcantly increased (Fig. 1B). Importantly, the
gene expression ratios of intronic-to canonical ACOX2 increased more
in moderately differentiated HCCs (mHCC) than in well-differentiated
HCCs (wHCC), suggesting the involvement of intronic-ACOX2 expres-
sion on HCC progression.
Discussion
This is the ﬁrst comprehensive transcriptional analysis of tissue
lesions of non-B, non-C HCC, background liver and NL using the 5′
SAGE method. Approximately 6.7% of our 5′SAGE tags showed no
matchingwithin the human genome, possibly due to the presence of a
single nucleotide polymorphism (SNP) in the human genome. Out of
the complete matched tags in the genome, 70% were assigned to
unique positions and 30% to two or more loci. The tags with multiple
matches with genomic loci were largely retrotransposon elements,
repetitive sequences, and pseudogenes.
In this study, the analysis of non-B, non-C HCC enabled us to
evaluate direct molecular changes associated with HCC without any
bias of gene induction by virus infection. The gene expression proﬁle
based on our 5′SAGE tags revealed that albumin (ALB) and
apolipoproteins were highly expressed in NL, indicating the massive
production of plasma proteins in NL; these results are similar to those
of our previous study using 3′SAGE [6]. Other genes such as aldolase B
(ALDOB), antitrypsin (SERPINA1), and haptoglobin (HP) were also
highly expressed in NL, in both the 5′SAGE and 3′SAGE libraries (Table
2) [6]. Comparison of the expression proﬁles among NL, background
NT and T identiﬁed several differentially expressed transcripts in T.
Galectin-4 (LGALS4) was up-regulated and HAMP, NNMT, CYP2E1,
and metallothionein were down-regulated in HCC in accordance with
previous ﬁndings (Table 3a) [8,9,21]. Moreover, CLEC4G, which was
predominantly expressed in the sinusoidal endothelial cells of the
liver, was down-regulated in HCC. In addition, we ﬁrst found that P
antigen family, member 2 (PAGE2) and XAGE1A were up-regulated in
HCC (Table 3a, Supplemental Fig. 1). These genes were members of
cancer-testis antigen that include MAGE-family genes. MAGE-family
members were originally found to be up-regulated in HCV-related
HCC, and reported to be useful as molecular markers and as possible
targetmolecules for immunotherapy in humanHCC [22]. In this study,
we identiﬁed that these members of genes were also up-regulated in
non B, non-C HCC. Thus, these genes may be useful as molecular
markers and therapeutic targets for the treatment of a certain type of
human HCC.
There existed some discrepancy between 5′SAGE and 3′SAGE
results, even though they were derived from the same sample.
Technical issues such as amplication error, difference of restriction
enzyme, and annotation error have been described previously [14]. It
is possible that 3′ transcripts might be more stable than 5′ transcripts
by binding of ribosomal proteins during translation. Another
possibility is the diversity of the transcriptional start and/or
termination sites. One of the advantages of 5′SAGE analysis is the
potential to determine the transcriptional start sites in each gene.
Indeed, a recent study indicated the importance of an insulin splice
variant in the pathogenesis of insulinomas [23]. Considering the
diversity of 5′ends of genes, it is more appropriate to perform 5′SAGE
in combination with 3′SAGE when determining the frequency of gene
expression and identifying novel transcript variants.
Here, we were able to identify at least 12 intron-origin transcripts
that were differentially expressed in HCC compared with the
background liver or NL. These transcripts could not be identiﬁed by
the 3′SAGE approach. We also performed detailed expression analysis
of ACOX2 that was involved in the beta-oxidation of peroxisome. We
Fig. 1. (A) RT-PCR results of ACOX2 and ACOX2 intronic RNAs in independent NL, NT (non-B, non-C), and T (non-B, non-C) samples. RT-PCR was performed in triplicate for each
sample-primer set from cDNA. The PCR products were semi-quantitatively analyzed with ImageJ software and calculated as levels relative to polymerase (RNA) II (DNA directed)
polypeptide L (POLR2L). The bar graph indicates the expression ratio of intronic-ACOX2-1 to canonical ACOX2. The expression pattern of intron 1 was different from that of canonical
ACOX2. (B) RTD-PCR analysis of ACOX2 and ACOX2 intronic RNAs in NL, T (HBV-related, HCV-related, and non-B, non-C), and NT tissues. Quantitative RTD-PCR was performed in
duplicate for each sample-primer set from cDNA. Each samplewas normalized relative to POLR2L. All HCC tissues were pathologically diagnosed aswell differentiated HCC (wHCC) or
moderately differentiated HCC (mHCC). Kruskal–Wallis tests and Mann–Whitney U tests were used for statistical analysis. ACOX2, acyl-Coenzyme A oxidase 2; HCC, hepatocellular
carcinoma; NL, normal liver; NT, non-tumor; RT-PCR, reverse transcriptase-polymerase chain reaction; RTD-PCR, real-time detection-PCR; T, tumor. ⁎Pb0.01, #Pb0.05.
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2) for the ﬁrst time and found that intronic-ACOX2-1was signiﬁcantly
overexpressed in T compared with NT and NL. The ratio of intronic-
ACOX2-1 and canonical ACOX2 (relative intronic-ACOX2) was progres-
sively up-regulated from NL via the background liver to HCC.
Importantly, the expression of relative intronic-ACOX2 was more up-
regulated inmoderately differentiated HCC than in well-differentiated
HCC. The intronic difference in expression might be due to a poly-
morphism, since the 5′SAGE library for NL and T were from different
people. The mechanisms of stepwise increase of intronic-ACOX2 in the
process of hepatocarinogenesis should be clariﬁed in future.
ACOX2 is a rate-limiting enzyme of branched-chain acyl-CoA
oxidase involved in the degradation of long branched fatty acid and
bile acid intermediates in peroxisomes. ACOX2 expression was
associated with the differentiation state of hepatocytes and was
repressed under the undifferentiated phase of human hepatoma cell
lines [24]. A decreased ACOX2 expression was also reported in
prostate cancer [25]. Here, the expression of canonical ACOX2 was
decreased, while that of intronic-ACOX2-1 was increased in HCC. The
deduced amino acid of intronic-ACOX2-1 encodes the C-terminal
(from 386 to 681 amino acids) of canonical ACOX2, lacking the active
sites for FAD binding and a fatty acid as the substrate, suggesting that
the protein may be functionally departed [26]. The biological role ofthe increased intronic-ACOX2-1 was not clear, but it might be
reﬂected by the activation of peroxisome proliferators-activated
receptor alpha (PPARA). It is reported that mice lacking ACOX1,
another rate-limiting enzyme in peroxisomal straight-chain fatty acid
oxidation, developed steatosis and HCC characterized by increased
mRNA and protein expression of genes regulated by PPARα [27]. The
importance of PPARα activation in HCC development has been
recently reported using HCV core protein transgenic mice [28].
Moreover, the overexpression of alpha-methylacyl-CoA racemase
(AMACR), an enzyme for branched-chain fatty acid beta-oxidation, is
reported to be a reliable diagnostic marker of prostate cancer and is
associated with the decreased expression of ACOX2 [25]. Therefore,
the expression of intronic-ACOX2-1 might open the door for further
investigations of their potential clinical use, e.g., serving as diagnostic
markers of HCC, although the functional relevance of this gene should
be further clariﬁed.
In conclusion, we report the ﬁrst comprehensive transcriptional
analysis of non-B, non-C HCC, NT background liver, and NL tissue,
based on 5′SAGE. This study offers new insights into the transcrip-
tional changes that occur during HCC development as well as the
molecular mechanism of carcinogenesis in the liver. The results
suggest the presence of unique intron-origin RNAs that are useful as
diagnostic markers and may be used as new therapeutic targets.
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Samples
Samples were obtained from a 56-year-old man who had
undergone surgical hepatic resection for the treatment of solitary
HCC. Serological tests for hepatitis B surface (HBs) antigen and anti-
HCV antibodies were negative. Tumor (T) and non-tumor (NT) tissue
samples were separately obtained from the tumorous parts (diag-
nosed as moderately differentiated HCC) and non-tumorous parts
(diagnosed as mild chronic hepatitis: F1A1) of the resected tissue. We
also obtained ﬁve normal liver (NL) tissue samples from ﬁve patients
who had undergone surgical hepatic resection because of metastatic
liver cancer. None of the patients was seropositive for both HBs
antigen and anti-HCV antibodies. Neither heavy alcohol consumption
nor the intake of chemical agents was observed before surgical
resection. All laboratory values related to hepatic function were
within the normal range. All procedures and risks were explained
verbally and provided in a written consent form.
We additionally used independent four NL tissue samples, 19 HBV-
HCCs, 20 HCV-HCCs and 4 non-B, non-C HCCs, and their background
liver tissue samples for reverse transcriptase-polymerase chain
reaction (RT-PCR) and real-time detection (RTD)-PCR (Supplemental
Table 1). Four non-B, non-C HCCs were histologically diagnosed as
moderately differentiated HCCs, and the adjacent non-cancerous liver
tissues were diagnosed as a normal liver, a chronic hepatitis, a pre-
cirrhotic liver and a cryptogenic liver cirrhosis, respectively. None of
the patients was seropositive for HBs antigen, anti-HBs antibodies,
anti-hepatitis B core (HBc) antibodies and anti-HCV antibodies.
Neither heavy alcohol consumption nor the intake of chemical agents
was observed. Histological grading of the tumor was evaluated by two
independent pathologists as described previously [16].
Generation of the 5′ SAGE library
5′SAGE librarieswere generated as previously described [14]. Five to
ten micrograms of poly(A)+RNA was treated with bacterial alkaline
phosphatase (BAP; TaKaRa, Otsu, Japan). Poly(A)+RNA was extracted
twice with phenol: chloroform (1:1), ethanol precipitated, and then
treated with tobacco acid pyrophosphatase (TAP). Two to four
micrograms of the BAP-TAP-treated poly(A)+RNA was divided into
two aliquots and an RNA linker containing recognition sites for EcoRI/
MmeI was ligated using RNA ligase (TaKaRa): one aliquot was ligated
to a 5′-oligo 1 (5′-GGAUUU GCUGGU GCAGUA CAA CGA AUU CCGAC-
3′) linker, and the other aliquot was ligated to a 5′-oligo 2 (5′-CUG CUC
GAA UGC AAG CUU CUG AAU UCC GAC-3′) linker. After removing
unligated 5′-oligo, cDNA was synthesized using RNaseH-free reverse-
transcriptase (Superscript II, Invitrogen, Carlsbad, CA, USA) at 12 °C for
1 h and 42 °C for the next hour, using 10 pmol of dT adapter-primer (5′-
GCGGCTGAAGACGGCCTATGTGGCCTT TTT TTTTTT TTT TTT-3′). After
ﬁrst-strand synthesis, RNA was degraded in 15 mM NaOH at 65 °C for
1 h. cDNAwas ampliﬁed in a volume of 100 μl by PCRwith 16 pmol of 5′
(5′ [biotin]-GGA TTT GCT GGT GCA GTA CAA-3′ or 5′[biotin]-CTG CTC
GAA TGC AAG CTT CTG-3′) and 3′ (5′-GCGGCT GAA GAC GGC CTA TGT-
3′) PCR primers. cDNAwas ampliﬁed using 10 cycles at 94 °C for 1 min,
58 °C for 1min, and72 °C for 2min. PCRproductsweredigestedwith the
MmeI type IIS restriction endonuclease (NEB, Pickering, Ontario,
Canada). The digested 5′-terminal cDNA fragments were bound to
streptavidin-coated magnetic beads (Dynal, Oslo, Norway). cDNA
fragments that bound to the beads were directly ligated together in a
reaction mixture containing T4 DNA ligase in a supplied buffer for 2.5 h
at 16 °C. The ditags were ampliﬁed by PCR using the following primers:
5′GGATTTGCTGGTGCAGTACA3′ and5′CTGCTCGAATGCAAGCTTCT
3′. The PCR products were analyzed by polyacrylamide gel electropho-
resis (PAGE) and digested with EcoRI. The region of the gel containing
the ditags was excised and the fragments were self-ligated to producelong concatamers that were then cloned into the EcoRI site of pZero 1.0
(Invitrogen). Colonieswere screenedbyPCRusing theM13 forward and
reverse primers. PCR products containing inserts of more than 600 bp
were sequenced with Big Dye terminator ver.3 and analyzed using a
3730 ABI automated DNA sequencer (Applied Biosystems, Foster City,
CA, USA). All electrophoretogramswere reanalyzed by visual inspection
to check for ambiguous bases and to correct misreads. In this study, we
obtained 19–20 bp tag information.
Association of the 5′SAGE tags with their corresponding genes
We attempted to align our 5′tags with the human genome (NCBI
build 36, available from http://www.genome.ucsc.edu/) using the
alignment program ALPS (http://www.alps.gi.k.u-tokyo.ac.jp/). Only
tags that matched in sense orientation were considered in our analysis.
The RefSeq database was searched for transcripts corresponding to the
regions adjacent to the alignment location of each 5′tag.
RT-PCR
Total RNA was extracted using a ToTally RNA extraction kit
(Ambion, Inc., Austin, TX, USA). Total RNA (500 ng) was reverse-
transcribed in a 100-μl reaction solution containing 240 U of Moloney
murine leukemia virus reverse transcriptase (Promega, Madison, WI,
USA), 80 U of RNase inhibitor (Promega), 4.6 mMMgCl2, 6.6 mM DTT,
1 mM dNTPs, and 2 mM random hexamer (Promega), at 42 °C for 1 h.
PCR was performed in a 20-μl volume containing 0.5 U of AmpliTaq
DNA polymerase (Applied Biosystems), 16.6 mM (NH4)2SO4, 67 mM
Tris–HCl, 6.7 mM MgCl2, 10 mM 2-mercaptoethanol, 1 mM dNTPs,
and 1.5 μM sense and antisense primers, using an ABI 9600 thermal
cycler (Applied Biosystems). The ampliﬁcation protocol included 28–
30 cycles of 95 °C for 45 s, 58 °C for 1 min, and 72 °C for 1 min. Primer
sequences are shown in Supplemental Table 2. RT-PCR was
performed in triplicate for each sample-primer set. Each sample
was normalized relative to polymerase (RNA) II (DNA directed)
polypeptide L (POLR2L). POLR2L is a housekeeping gene that showed
relatively stable gene expression in various tissues [29]. The PCR
products were semi-quantitatively analyzed with ImageJ software
(http://rsb.info.nih.gov/ij/).
RTD-PCR
Intron-origin transcript expression was quantiﬁed using TaqMan
UniversalMasterMix (AppliedBiosystems). The sampleswere ampliﬁed
using an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems). Using the standard curve methods, quantitative PCR was
performed in duplicate for each sample-primer set. Each sample was
normalized relative toPOLR2L. Theassay IDs usedwereHs00185873_m1
for ACOX2 and Hs00360764_m1 for POLR2L. The speciﬁc primers and
probe sequence of intronic-ACOX2-1 were 5′-TTCATAAAGTTGTGAGCA-
GAGGAAA-3′ (forward), 5′-TGCACCACTTACTGAGCATCTACTC-3′ (re-
verse), and 5′-ACTTCTTACCTCAGAGCTG-3′ (probe).
Analysis of pathway network
MetaCore™ software (GeneGo Inc., St. Joseph, MI) was used to
investigate the molecular pathway networks of non-B, non-C HCC,
HBV-HCC and HCV-HCC. All genes up-regulated more than ﬁve-fold in
all HCC libraries subjected to Enrichment analysis in GO process
networks by default settings (pb0.05).
Statistical analysis
Kruskal–Wallis tests were used to compare the expression among
normal liver, non-cancerous tissues, and HCC tissues. Mann–Whitney
U tests were also used to evaluate the statistical signiﬁcance of ACOX2
223Y. Hodo et al. / Genomics 95 (2010) 217–223gene expression levels between two groups. All statistical analyses
were performed using R (http://www.r-project.org/).
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